The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
The Mechanism of Action of Novel Antipsychotic Drugs
Open accessAbstract
It is no longer tenable to attribute all the antipsychotic action of antipsychotic drugs to dopamine (DA) D2 receptor blockade and subsequent development of depolarization inactivation of the mesolimbic or mesocortical DA neurons. The chief evidence for this position is that clozapine (CLOZ) does not differ from typical antipsychotic drugs in these regards but is more effective than typical neuroleptic drugs. The mechanism of action of atypical antipsychotic drugs related to CLOZ may involve reduction of dopaminergic activity in the mesolimbic system by a variety of mechanisms, including D1 and D2 receptor blockade. Relatively higher affinity for the serotonin (5HT)2 receptor than for the D2 receptor may also be important to the action of CLOZ-like compounds. Enhanced DA release in the mesocortical system may be relevant to the effectiveness of these agents in treating negative symptoms. Several other classes of new agents alter the dopaminergic system by means of alternative mechanisms. Partial DA agonists may modulate DA neurotransmission more adequately than pure antagonists by producing a mix of direct agonist and antagonistic effects. DA autoreceptor agonists and 5HT3 antagonists appear to act by diminishing the release of DA from some, but not all, DA neurons. Substituted benzamides are "pure" D2 antagonists with some in vivo selectivity for limbic D2 over striatal D2 receptors. Highly selective D1 antagonists have been proposed to produce equivalent antipsychotic activity and fewer extrapyramidal symptoms than D2 antagonists. Antagonists of the recently identified D3 receptors are being sought. Excessive stimulation of the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, leading to neurotoxicity or diminished activation of this receptor, is the target of novel approaches to treating schizophrenia. Phencyclidine (PCP) antagonists that would activate the NMDA receptor and sigma receptor antagonists are of interest as antipsychotic agents. Therapeutic strategies for treating schizophrenia, schizophrenia-related disorders, and other psychoses will likely be genuinely diverse in the next decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,893
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Multiple receptors for dopamine
Kebabian, J. W., & Calne, D. B. (1979) · Nature · doi:10.1038/277093a0 · Cited by 3,725
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Psychopharmacology: The Third Generation of Progress.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,014
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Self-citationThe Journal of Neuropsychiatry and Clinical Neurosciences
Bowden, V. M. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110111047 · Cited by 1,223
Advances in biochemical psychopharmacology
Aprison, M. H. (1970) · Neuropharmacology · doi:10.1016/0028-3908(70)90062-6 · Cited by 1,175
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Self-citationBogerts, B. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790310046006 · Cited by 880
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
Stevens, J. R. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.04200020023003 · Cited by 722
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
Farde, L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250087012 · Cited by 692
Chiodo, L., & Bunney, B. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680
Clark, D., & White, F. J. (1987) · Synapse · doi:10.1002/syn.890010408 · Cited by 660
Meltzer, H. Y. (1989) · Psychopharmacology · doi:10.1007/bf00442554 · Cited by 602
Self-citationDifferential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons
White, F. J., & Wang, R. Y. (1983) · Science · doi:10.1126/science.6136093 · Cited by 588
Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity
Bunney, B. S., & Grace, A. A. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90471-x · Cited by 549
Frontiers in Catecholamine Research
IVERSEN, L. L. (1976) · Biochemical Society Transactions · doi:10.1042/bst0040186a · Cited by 448
Naunyn-Schmiedeberg's archives of pharmacology: European Journal of Physiology
(1975) · Klinische Wochenschrift · doi:10.1007/bf01482719 · Cited by 446
Biochemical profile of risperidone, a new antipsychotic.
Leysen, J. E., Gommeren, W., Eens, A., de Chaffoy de Courcelles, D., Stoof, J. C., & Janssen, P. A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13416-2 · Cited by 411
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
Deakin, J. F. W., Slater, P., Simpson, M. D. C., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., & Cross, A. J. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07257.x · Cited by 386
Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism
MILLER, R. J., & HILEY, C. R. (1974) · Nature · doi:10.1038/248596a0 · Cited by 381
Specific [3H]phencyclidine binding in rat central nervous system.
Zukin, S. R., & Zukin, R. S. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.10.5372 · Cited by 380
Receptors for neurotransmitters and peptide hormones.
Pepeu, G., Kuhar, M. J., & Enna, S. J. (1980) · PubMed · Cited by 376
Hervé, D., Pickel, V. M., Joh, T. H., & Beaudet, A. (1987) · Brain Research · doi:10.1016/0006-8993(87)91588-5 · Cited by 372
The organization of divergent axonal projections from the midbrain raphe nuclei in the rat
Imai, H., Steindler, D. A., & Kitai, S. T. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902430307 · Cited by 369
Cellular and Molecular Neurobiology
(2001) · Elsevier eBooks · doi:10.1016/c2009-0-02243-0 · Cited by 357
Costall, B., Domeney, A. M., Naylor, R. J., & Tyers, M. B. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11394.x · Cited by 355
Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors
Walters, J. R., & Roth, R. H. (1976) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00498834 · Cited by 350
D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
Farde, L., Wiesel, F. A., Nordstr�m, A. L., & Sedvall, G. (1989) · Psychopharmacology · doi:10.1007/bf00442555 · Cited by 325
Advances in biochemical psychopharmacology
Shanbour, L. L. (1971) · Neuropharmacology · doi:10.1016/0028-3908(71)90060-8 · Cited by 317
Grace, A. A., & Bunney, B. S. (1986) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24386-5 · Cited by 314
Dopamine receptor subtypes: beyond the D1/D2 classification
Andersen, P. H., Gingrich, J. A., Bates, M. D., Dearry, A., Falardeau, P., Senogles, S. E., & Caron, M. G. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90249-8 · Cited by 293
Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system
Andén, N.-E., & Stock, G. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10025.x · Cited by 291
Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain
Peroutka, S. J., U'Prichard, D. C., Greenberg, D. A., & Snyder, S. H. (1977) · Neuropharmacology · doi:10.1016/0028-3908(77)90023-5 · Cited by 288
Evidence for the existence of a raphe projection to the substantia nigra in rat
Dray, A., Gonye, T. J., Oakley, N. R., & Tanner, T. (1976) · Brain Research · doi:10.1016/0006-8993(76)90005-6 · Cited by 284
Hong, J. S., Yang, H. Y., Fratta, W., & Costa, E. (1978) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31211-5 · Cited by 283
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Self-citationClassification and nomenclature of phencyclidine and sigma receptor sites
Quirion, R., Chicheportiche, R., Contreras, P. C., Johnson, K. M., Lodge, D., William Tam, S., Woods, J. H., & Zukin, S. R. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90094-4 · Cited by 271
Ugedo, L., Grenhoff, J., & Svensson, T. H. (1989) · Psychopharmacology · doi:10.1007/bf00442004 · Cited by 267
Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes.
Vincent, J. P., Kartalovski, B., Geneste, P., Kamenka, J. M., & Lazdunski, M. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4678 · Cited by 263
Excitatory amino acids in health and disease.
Lodge, D. (1988) · Cited by 261
Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
(3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
Kornhuber, J., Mack-Burkhardt, F., Riederer, P., Hebenstreit, G. F., Reynolds, G. P., Andrews, H. B., & Beckmann, H. (1989) · Journal of Neural Transmission · doi:10.1007/bf01248936 · Cited by 250
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors
Hjorth, S., Carlsson, A., Wikström, H., Lindberg, P., Sanchez, D., Hacksell, U., Arvidsson, L.-E., Svensson, U., & Nilsson, J. L. G. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90448-3 · Cited by 229
Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics
Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y., & Tanaka, C. (1986) · Biological Psychiatry · doi:10.1016/0006-3223(86)90332-x · Cited by 222
Spinal and supraspinal components of cannabinoid-induced antinociception.
Lichtman, A. H., & Martin, B. R. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20242-7 · Cited by 217
Fibiger, H. C., & Miller, J. J. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90120-8 · Cited by 213
Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat
White, F. J., & Wang, R. Y. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90929-3 · Cited by 212
Ögren, S. O., Hall, H., Köhler, C., Magnusson, O., Lindbom, L.-O., Ängeby, K., & Florvall, L. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90567-3 · Cited by 212
Positive and Negative Schizophrenic Symptoms and the Role of Dopamine
Mackay, A. V. P. (1980) · British Journal of Psychiatry · doi:10.1192/bjp.137.4.379 · Cited by 210
Sayers, A. C., B�rki, H. R., Ruch, W., & Asper, H. (1975) · Psychopharmacologia · doi:10.1007/bf00421063 · Cited by 206
Largent, B. L., Gundlach, A. L., & Snyder, S. H. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.15.4983 · Cited by 196
Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
Nishikawa, T., Takashima, M., & Toru, M. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90046-0 · Cited by 196
Ljungberg, T., & Ungerstedt, U. (1978) · Psychopharmacology · doi:10.1007/bf00432845 · Cited by 196
Chiodo, L., & Bunney, B. (1985) · The Journal of Neuroscience · doi:10.1523/jneurosci.05-09-02539.1985 · Cited by 195
EFFECT OF IMPULSE FLOW ON THE RELEASE AND SYNTHESIS OF DOPAMINE IN THE RAT STRIATUM
Roth, R. H., Walters, J. R., & Aghajanian, G. K. (1973) · Elsevier eBooks · doi:10.1016/b978-0-08-017922-3.50103-9 · Cited by 186
New Antipsychotics: Classification, Efficacy, and Adverse Effects
Gerlach, J. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.289 · Cited by 181
ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA
Kerwin, R. W., Patel, S., Meldrum, B. S., Czudek, C., & Reynolds, G. P. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91371-2 · Cited by 177
Anthony Altar, C., Wasley, A. M., Neale, R. F., & Stone, G. A. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90181-4 · Cited by 176
Effect of impulse flow on the release and synthesis of dopamine in the striatum
Roth, R. H., Walters, J. R., & Aghajanian, G. K. (1973) · Life Sciences · doi:10.1016/0024-3205(73)90387-1 · Cited by 174
Effect of clozapine on human serum prolactin levels
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.12.1550 · Cited by 171
Modulation of striatal [3H]-glutamic acid release by dopaminergic drugs
Mitchell, P. R., & Doggett, N. S. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90592-5 · Cited by 169
Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra
Nedergaard, S., Bolam, J. P., & Greenfield, S. A. (1988) · Nature · doi:10.1038/333174a0 · Cited by 166
Activation of a 5-HT3 receptor releases dopamine from rat striatal slice
Blandina, P., Goldfarb, J., & Green, J. P. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90528-6 · Cited by 159
Bowen, W. D., Moses, E. L., Tolentino, P. J., & Walker, J. M. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90260-d · Cited by 154
Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
Arora, R. C., & Meltzer, H. Y. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244654 · Cited by 154
Self-citationDemonstration of [3H]cyclazocine binding to multiple opiate receptor sites.
Zukin, R. S., & Zukin, S. R. (1981) · PubMed · Cited by 151
Živković, B., Guidotti, A., Revuelta, A., & Costa, E. (1975) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30226-0 · Cited by 147
Galloway, M. P., Wolf, M. E., & Roth, R. H. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38969-x · Cited by 144
Clinical Pharmacology of NSAIDs
Brater, D. C. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03171.x · Cited by 137
Receptor mechanisms in antipsychotic drug action: focus on sigma receptors
Snyder, S. H., & Largent, B. L. (1989) · Journal of Neuropsychiatry · doi:10.1176/jnp.1.1.7 · Cited by 137
Haertzen, C. A. (1970) · Psychopharmacology · doi:10.1007/bf00402763 · Cited by 126
Cohen, B. M., & Lipinski, J. F. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90111-6 · Cited by 125
Effects of clozapine on cerebral catecholaminergic neurone systems
Bartholini, G., Haefely, W. E., Jalfre, M., Keller, H. H., & Pletscher, A. (1972) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1972.tb06898.x · Cited by 124
Potential antipsychotic BMY 14802 selectively binds to sigma sites
Taylor, D. P., & Dekleva, J. (1987) · Drug Development Research · doi:10.1002/ddr.430110109 · Cited by 124
Jasinski, D. R., Martin, W. R., & Sapira, J. D. (1968) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196892215 · Cited by 121
Hervé, D., Simon, H., Blanc, G. ́., Moal, M. L., Glowinski, J., & Tassin, J. (1981) · Brain Research · doi:10.1016/0006-8993(81)90144-x · Cited by 117
O’Dell, S. J., LaHoste, G. J., Widmark, C., Shapiro, R. M., Potkin, S. G., & Marshall, J. F. (1990) · Synapse · doi:10.1002/syn.890060205 · Cited by 112
Dopamine and the pharmacology of schizophrenia: The state of the evidence
Matthysse, S. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90081-8 · Cited by 109
Norepinephrine in Acute Exacerbations of Chronic Schizophrenia
van Kammen, D. P. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140061009 · Cited by 108
Hand, T. H., Hu, X., & Wang, R. Y. (1987) · Brain Research · doi:10.1016/0006-8993(87)90207-1 · Cited by 107
B�rki, H. R., Ruch, W., & Asper, H. (1975) · Psychopharmacology · doi:10.1007/bf00421302 · Cited by 106
Andersen, P. H., & Bræstrup, C. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb13094.x · Cited by 104
Behavioral implications of dopaminergic neurons in the mesolimbic system.
Sd, I., & Koob, G. F. (1977) · PubMed · Cited by 101
Blaha, C. D., & Lane, R. F. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90633-1 · Cited by 98
Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo
Andersen, P. H., Nielsen, E. B., Grønvald, F. C., & Bræstrup, C. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90656-4 · Cited by 97
Castelão, J., Ferreira, L., Gelders, Y. G., et al. (1989) · Schizophrenia Research · doi:10.1016/0920-9964(89)90034-0 · Cited by 96
Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and Clinical Studies
Meltzer, H. Y. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.3.456 · Cited by 95
Self-citationRupniak, N. M. J., Hall, M. D., Mann, S., et al. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90577-5 · Cited by 93
Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex
Matsubara, S., & Meltzer, H. Y. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90027-1 · Cited by 93
Self-citationSorensen, S. M., Humphreys, T. M., & Palfreyman, M. G. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90402-0 · Cited by 92
Hervé, D., Simon, H., Blanc, G., Lisoprawski, A., Moal, M. L., Glowinski, J., & Tassin, J. (1979) · Neuroscience Letters · doi:10.1016/0304-3940(79)96101-9 · Cited by 89
PCP (phencyclidine), historical and current perspectives
Domino, E. F. (1981) · Medical Entomology and Zoology · Cited by 88
Drew, K. L., O'Connor, W. T., Kehr, J., & Ungerstedt, U. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90366-e · Cited by 84
Biochemical pharmacology of the atypical neuroleptic remoxipride
Köhler, C., Hall, H., Magnusson, O., Lewander, T., & Gustafsson, K. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05282.x · Cited by 83
Clozapine—A serotonin antagonist?
Fink, H., Morgenstern, R., & Oelssner, W. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(84)90297-1 · Cited by 80
Wiesel, F., & Sedvall, G. (1975) · European Journal of Pharmacology · doi:10.1016/0014-2999(75)90123-5 · Cited by 80
Alfredsson, G., Wiesel, F.-A., & Tylec, A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90052-2 · Cited by 77
Rasmussen, K., & Aghajanian, G. K. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90001-2 · Cited by 76
Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors
Reynolds, G. P., Garrett, N. J., Rupniak, N. M. J., Jenner, P. G., & MARSDEN, C. D. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90517-4 · Cited by 76
The role of excitatory amino acids in neuropsychiatric illness
Javitt, D. C., & Zukin, S. R. (1990) · Journal of Neuropsychiatry · doi:10.1176/jnp.2.1.44 · Cited by 75
Kelland, M. D., Freeman, A. S., & Chiodo, L. A. (1989) · Synapse · doi:10.1002/syn.890030105 · Cited by 74
Stawarz, R. J., Hill, H. F., Robinson, S. E., et al. (1975) · Psychopharmacology · doi:10.1007/bf00421014 · Cited by 73
Ichikawa, J., & Meltzer, H. Y. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22988-3 · Cited by 73
Self-citationLane, R. F., & Blaha, C. D. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90042-6 · Cited by 72
Clozapine increases rat serum prolactin levels
Meltzer, H. Y., Daniels, S., & Fang, V. S. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90482-8 · Cited by 71
Self-citationComparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
Zahniser, N. R., & Dubocovich, M. L. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22033-x · Cited by 69
Meltzer, H. Y., So, R., Miller, R. J., & Fang, V. S. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90551-4 · Cited by 69
Self-citationSeeger, T., Thal, L. J., & Gardner, E. L. (1982) · Psychopharmacology · doi:10.1007/bf00435275 · Cited by 67
Electrochemistry in Vivo: Application to CNS Pharmacologya
Lane, R. F., & Blaha, C. D. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb23603.x · Cited by 66
Murray, A. M., & Waddington, J. L. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)94062-3 · Cited by 64
Glutamate in schizophrenics and healthy controls
Gattaz, W. F., Gattaz, D., & Beckmann, H. (1982) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00343292 · Cited by 64
Drug-induced changes of dopamine turnover in striatum and limbic system of the rat
Bartholini, G., Keller, H. H., & Pletscher, A. (1975) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1975.tb09476.x · Cited by 63
Regulation of dopamine synthesis in the medial prefrontal cortex: studies in brain slices.
Wolf, M. E., Galloway, M. P., & Roth, R. H. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38930-5 · Cited by 61
N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis.
Koek, W., Woods, J. H., & Colpaert, F. C. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13197-2 · Cited by 60
See, R. E., Toga, A. W., & Ellison, G. (1990) · Journal of Neural Transmission · doi:10.1007/bf01245166 · Cited by 60
Hirose, A., Kato, T., Ohno, Y., Shimizu, H., Tanaka, H., Nakamura, M., & Katsube, J. (1990) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.53.321 · Cited by 60
Salin, P., Mercugliano, M., & Chesselet, M. ‐. (1990) · Cellular and Molecular Neurobiology · doi:10.1007/bf00733640 · Cited by 60
Impérato, A., & Angelucci, L. (1989) · PubMed · Cited by 60
Ichikawa, J., & Meltzer, H. Y. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90033-3 · Cited by 59
Self-citationExcitotoxicity and N‐methyl‐D‐Aspartate receptors
Olney, J. W. (1989) · Drug Development Research · doi:10.1002/ddr.430170406 · Cited by 59
Dopamine Autoreceptors Modulate Dopamine Release from the Prefrontal Cortex
Talmaciu, R. K., Hoffmann, I., & Cubeddu, L. X. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb00691.x · Cited by 59
hle, L. S., Collin, A.-K., & Ungerstedt, U. (1990) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00166955 · Cited by 56
Phencyclidine as an indirect dopamine agonist [proceedings].
Meltzer, H. Y., Sturgeon, R. D., Simonovic, M., & Fessler, R. G. (1980) · PubMed · Cited by 56
Self-citationCholinergic mediation of the discriminative stimulus properties of clozapine
Nielsen, E. B. (1988) · Psychopharmacology · doi:10.1007/bf00735891 · Cited by 55
Coward, D. M., Dixon, A. K., Urwyler, S., White, T. G., Enz, A., Karobath, M. E., & Shearman, G. T. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13343-0 · Cited by 54
Antagonism of fenfluramine-induced hyperthermia: A measure of central serotonin inhibition
Sulpizio, A. C., Fowler, P. J., & Macko, E. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90638-0 · Cited by 54
Sertraline potently displaces (+)-[3H]3-PPP binding to σ sites in rat brain
Schmidt, A. W., Lebel, L. A., Koe, B. K., Seeger, T., & Heym, J. H. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90734-6 · Cited by 53
Plantjé, J. F., Steinbusch, H. W. M., Schipper, J., Dijcks, F. A., Verheijden, P. F. H. M., & Stoof, J. C. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90009-1 · Cited by 51
Murray, A. M., & Waddington, J. L. (1989) · Psychopharmacology · doi:10.1007/bf00444699 · Cited by 49
Nylander, I., & Terenius, L. Y. (1986) · Brain Research · doi:10.1016/0006-8993(86)91426-5 · Cited by 49
Evidence for dopamine autoreceptors in mesocortical dopamine neurons
Fadda, F., GESSA, G. L., Marcou, M., Mosca, E., & Rossetti, Z. L. (1984) · Brain Research · doi:10.1016/0006-8993(84)91453-7 · Cited by 49
Receptors and Ligands in Psychiatry
Perry, B. D. (1989) · Journal of Neuropsychiatry · doi:10.1176/jnp.1.1.94-a · Cited by 49
Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors
Criswell, H. E., Mueller, R. A., & Breese, G. R. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90698-5 · Cited by 47
Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons
Souto, M., Monti, J. M., & Altier, H. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90160-6 · Cited by 41
Mayer, M. L., Vyklický, L., & Sernagor, E. (1989) · Drug Development Research · doi:10.1002/ddr.430170404 · Cited by 40
Compton, D. M., & Johnson, K. M. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23733-8 · Cited by 39
Kilts, C., Anderson, C., Ely, T. D., & Jk, N. (1987) · Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03961.1987 · Cited by 36
Multiple Dopamine Receptors in Brain and the Pharmacological Action of Substituted Benzamide Drugs
Jenner, P. G., & MARSDEN, C. D. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb06863.x · Cited by 36
Clozapine: Mechanism of Action in Relation to its Clinical Advantages
Meltzer, H. Y. (1990) · International perspectives series : psychiatry, psychology, and neurosciences · doi:10.1007/978-1-4612-3248-3_11 · Cited by 35
Self-citationNovel approaches to the pharmacotherapy of schizophrenia
Meltzer, H. Y. (1986) · Drug Development Research · doi:10.1002/ddr.430090105 · Cited by 35
Self-citationHetey, L. (1986) · Neuropharmacology · doi:10.1016/0028-3908(86)90157-7 · Cited by 34
Neostriatal and mesolimbic neurons: Dose-dependent effects of clozapine
Rebec, G. V., Bashore, T. R., Zimmerman, K. S., & Alloway, K. D. (1980) · Neuropharmacology · doi:10.1016/0028-3908(80)90151-3 · Cited by 31
Studies on the Mechanism of Action of Substituted Benzamide Drugs
Köhler, C., Ögren, S. O., & Fuxé, K. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb06864.x · Cited by 30
Ichikawa, J., & Meltzer, H. Y. (1990) · Brain Research · doi:10.1016/0006-8993(90)90532-g · Cited by 29
Self-citationParashos, S. A., Marı́n, C., & Chase, T. N. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90031-1 · Cited by 29
Synergistic blockade of some dopamine-mediated behaviours by (?)-sulpiride and SCH 23390 in the rat
Dall’Olio, R., Roncada, P., Vaccheri, A., et al. (1989) · Psychopharmacology · doi:10.1007/bf00451685 · Cited by 23
Vasse, M., & Protais, P. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90141-0 · Cited by 23
Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity
Carvey, P. M., Kao, L. C., Zhang, T. J., Amdur, R. L., Lin, D. H., Singh, R., & Klawans, H. L. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90158-e · Cited by 22
The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity
Carvey, P. M., Kao, L. C., Tanner, C. M., Goetz, C. G., & Klawans, H. L. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90540-6 · Cited by 22
Andén, N. ‐., Grenhoff, J., & Svensson, T. H. (1988) · Psychopharmacology · doi:10.1007/bf02180041 · Cited by 22
Halperin, R., Guerin, J. J., & Davis, K. L. (1989) · Psychopharmacology · doi:10.1007/bf00451692 · Cited by 18
Johnson, K. M., Snell, L. D., Sacaan, A. I., & Jones, S. M. (1989) · Drug Development Research · doi:10.1002/ddr.430170405 · Cited by 18
Fjalland, B. (1979) · Psychopharmacology · doi:10.1007/bf00429687 · Cited by 16
Carvey, P. M., Hitri, A., Goetz, C. G., Tanner, C. M., & Klawans, H. L. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90372-4 · Cited by 16
Hu, X., & Wang, R. Y. (1989) · Brain Research · doi:10.1016/0006-8993(89)90519-2 · Cited by 10
Carvey, P. M., Nath, S. T., Kao, L. C., Zhang, T. J., Lin, D. H., Singh, R., Amdur, R. L., & Klawans, H. L. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90665-s · Cited by 8
Cited by
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Metadata
- Authors
- Meltzer, H. Y.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-01-01
- Volume
- 17
- Issue
- 2
- Pages
- 263-287
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2131083220
- Cited by
- 411
- References
- 166
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.